نبذة مختصرة : The drug interaction potential of enarodustat (doses: 25, 50 mg) on the activity of cytochrome P450 (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4 was evaluated after once-daily administration for 15 days in a phase 1 multiple-ascending-dose study in healthy subjects. Probe substrates specific for the enzymes, i.e., caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4), were administered orally as a cocktail with (day 15) and without (day -3) enarodustat. Drug interaction was based on geometric mean maximum plasma concentration (C max ) and area under the plasma concentration-time curve from the time of dosing to infinity (AUC inf ) ratios (day 15/day -3) for CYP1A2, 2C9, 2C19, 2D6, 3A4, and urinary excretion of dextromethorphan metabolite dextrorphan for CYP2D6. At the 2 enarodustat doses, for caffeine, the geometric mean ratios (range) for C max and AUC inf were 0.99-1.06 and 1.61-1.63, respectively. The ratios for peak concentrations and total exposures were 0.98-1.07 and 0.71-1.78 for tolbutamide and omeprazole, respectively. For dextrorphan the C max and AUC inf ratios were 0.83-0.90 and 1.02-1.04, respectively. The mean dextrorphan cumulative amount excreted into the urine from the time of dosing to 24 hours values on day -3 and day 15 were 8.25 mg and 8.20 mg at the lower dose, and 9.40 mg and 9.51 mg at the higher dose. The ratios for midazolam C max and AUC inf were 1.42-1.63. Overall, there was a lack of enarodustat dose dependency regarding the geometric mean ratios and 90% confidence intervals and urinary excretion of dextrorphan. There were some cases where the 90% confidence intervals at the 2 enarodustat doses were outside the 0.80-1.25 range, but changes in the geometric mean ratios were all <2-fold.
(© 2023, The American College of Clinical Pharmacology.)
References: Artunc F, Risler T. Serum erythropoietin concentrations and responses to anemia in patients with or without chronic kidney disease. Nephrol Dial Transplant. 2007;22:2900-2908.
Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol. 2006;26:261-268.
Suzuki S. What do new ESAs do? Kidney Dialysis. 2009;67:531-535 (Japanese).
Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Landau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. J Mol Med (Berl). 2007;85:1325-1330.
Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358:162-168.
Ogoshi Y, Matsui T, Mitani I, et al. Discovery of JTZ-951: a HIF prolyl hydroxylase inhibitor for the treatment of renal anemia. ACS Med Chem Lett. 2017;8:1320-1325.
Fujikawa R, Nagao Y, Fujioka M, et al. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: a review of the evidence. Ther Apher Dial. 2022;26(4):679-693.
Akizawa T, Nangaku M, Yamaguchi T, et al. A Phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney Int Rep. 2021;6(7):1840-1849.
Akizawa T, Nangaku M, Yamaguchi T, et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD Study. Kidney Dis (Basel). 2021;7(6):494-502.
Akizawa T, Nangaku M, Yamaguchi T, et al. Two long-term phase 3 studies of Enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies. Ther Apher Dial. 2022;26(2):345-356.
Legendre C, Hori T, Loyer P, et al. Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer. 2009;45(16):2882-2892.
Pai S, Huang MQ, Maki K, et al. A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1176:122754.
Boxenbaum H, Battle MJ. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763-766.
Pai S, Kambhampati SRP, Shinya N, Yamada H. Pharmacokinetics of enarodustat in non-Japanese and Japanese healthy subjects and in patients with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev. 2023;12:683-690.
Larrey D, Amouyal G, Tinel M, et al. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol. 1987;24(5):676-679.
de Andrés F, LLerena A. Simultaneous determination of cytochrome P450 oxidation capacity in humans: a review on the phenotyping cocktail approach. Curr Pharm Biotechnol. 2016;17(13):1159-1180.
Pai S, Connaire J, Yamada H, et al. A mass balance study of 14C-labeled JTZ-951 (enarodustat), a novel orally available erythropoiesis-stimulating agent, in patients with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev. 2020;9(6):728-741.
Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002;12(2):101-109.
Turpault S, Brian W, Van Horn R, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928-935.
Tennezé L, Verstuyft C, Becquemont L, et al. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther. 1999;66(6):582-588.
Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993;53(5):503-514.
Böttiger Y, Tybring G, Götharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-391.
Kawashima Y, Hagiwara M, Inoue Y, et al. Evaluation of dextromethorphan N demethylation activity as a biomarker for cytochrome P450 3A activity in man. Pharmacol Toxicol. 2002;90(2):82-88.
Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and KORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625-629.
Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90(2):328-332.
Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91(2): 321-326.
Wilkinson GR. In vivo probes for studying induction and inhibition of cytochrome P450 enzymes in humans. In: Rodrigues AD, ed. Drug-Drug Interactions. New York: Marcel Dekker, Inc; 2002:439-503.
Thorn CF, Aklillu E, McDonagh EM, et al. PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012;22(5):389-395.
Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377-390.
Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983;16(suppl 1):43S-49S.
Heizmann P, Ziegler WH. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung. 1981;31(12a):2220-2223.
Kato R, Matsura A, Kamiya R, et al. Effect of hypoxia on UDP-glucuronosyl transferase mRNA expression in human hepatocarcinoma functional liver celL4 cell line. Pharmazie. 2016;71(3):152-153.
Processing Request
No Comments.